Novartis
(https://pluvicto.com) 📸 Data Snapshot: May 30, 2026Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
The information density is exceptionally high for a public-facing medical site. It provides granular clinical trial data such as the median progression-free survival (9.3 months vs 5.6 months) and specific tumor response percentages (49% vs 14%) from the named PSMAfore trial. Power words are virtually absent in headings, which instead focus on functional utility such as ‘Important Safety Information’ and ‘Approved Use.’
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://pluvicto.com) PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: Man and his daughter standing with PLUVICTO V] PLUVICTO: Every day without progression is a VICTORYWhat Is PLUVICTO?What to expect with treatmentIn the PSMAfore trial, men with PSMA+ mCRPC who received PLUVICTO saw more time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy. In that study, 49% of men who received PLUVICTO saw their tumors shrink or disappear (vs 14% with a change in hormone therapy). [H5] Available before chemotherapy for PSMA+ mCRPC* *For certain men as determined by their doctor. [H2] How does targeted treatment work for PSMA+ mCRPC?Explore PLUVICTO [H2] Care partners: Find information and materials made for you.Care partner support [H2] Find downloadable materials with additional information.Get helpful materials [H1] Interested in receiving information about PLUVICTO? PLUVICTO® Pulse is a series of emails that helps you talk to your doctor about PLUVICTO.Sign up todayNext: About mCRPC >mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.
SUB-PAGE (https://pluvicto.com/about-pluvicto/how-pluvicto-works/) What Is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: Man standing inside PLUVICTO V] What IsPLUVICTO? [H2] PLUVICTO is different [H3] It's not chemotherapy. It's targeted treatment called radioligand therapy (RLT). [H4] The FIRST and ONLY RLT for PSMA+ mCRPC RLT is targeted radiation that is injected or infused. PLUVICTO is an RLT that targets a biomarker called PSMA. [H4] Remember it in 3 steps [IMG: PLUVICTO, healthy cells, and PSMA+ cancer cells] PLUVICTO is designed to find and attack PSMA+ cells. PSMA is found on many prostate cancer cells and also some healthy cells. [IMG: Pluvicto attaching to a PSMA+ prostate cancer cell] When PLUVICTO finds PSMA on the surface of a cell, it goes into the cell. [IMG: PLUVICTO entering a cancer cell] Once inside, PLUVICTO releases radiation, damaging or destroying the cell from within. It may also affect some nearby healthy cells. [IMG: Over [25,000] men have already taken PLUVICTO. It could be your next step.] [IMG: Bar chart icon] PLUVICTO has proven results across 2 trialsSee the data [IMG: Thumbnail of Comprehensive Brochure] [H4] Download the PLUVICTO Comprehensive Brochure Get all the information you need about treatment with PLUVICTO.DownloadCopy Link [H1] You’ll receive PLUVICTO at your closest PLUVICTO Treatment Center Treatment Center Locator< Previous: About mCRPCNext: Is PLUVICTO Right For Me? >mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
SUB-PAGE (https://pluvicto.com/treatment-center-locator/) Treatment Center Locator | PLUVICTO
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [H1] Find a PLUVICTO Treatment Center [H2] PLUVICTO is available at over 600 treatment centers across the United States. [H3] See below to find the PLUVICTO Treatment Center nearest you. If you need further details, including PLUVICTO availability and supply, please contact the treatment centerTreatment centers may have different patient eligibility criteriaPlease contact the treatment center directly for more information [H3] Please note that PLUVICTO Treatment Centers listed here are only those that have authorized their participation on our website. Please check back regularly, as this list will be periodically updated with newly certified locations.If you are having trouble finding a local treatment site, call the Novartis Patient SupportTM Team at 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidaysIf you are a healthcare professional and your site is not listed or you are interested in becoming a treatment center, contact Novartis Patient SupportTM Team at 1-844-638-7222 or your local sales specialist [IMG: Dosing cal icon] You’ll receive PLUVICTO at a treatment center for up to 6 dosesSee what to expect
SUB-PAGE · THIN (https://pluvicto.com/pluvicto-pulse/) Sign Up | PLUVICTO® (Lutetium Lu 177 vipivotide tetraxetan)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: Man playing with his golden retriever with Pluvicto V.] Sign Up ForMore Info [H4] If you or a loved one are considering treatment, PLUVICTO® Pulse can help you learn more It helps in 3 steps:Prepare to talk to your doctorExplore how PLUVICTO could helpKnow what to expect during treatment [IMG: Documents icon] Find additional resources to help prepare you for treatment Find helpful materials [H1] If you already have a prescription for PLUVICTO, call Novartis Patient Support™ at 1-844-638-7222 Learn more< Previous: Care Partner SupportNext: Helpful Materials >mCRPC, metastatic castration-resistant prostate cancer.
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
This page presents a snapshot of public data from Novartis, captured on May 30, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Novartis: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://pluvicto.com to view the most current version of its content and see directly what this company is about and what it offers.